Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases

por Goldstein, Iris M, Roisman, Laila C, Keren-Rosenberg, Shoshana, Dudnik, Julia, Nechushtan, Hovav, Shelef, Ilan, Fuchs, Vered, Kian, Waleed, Peled, Nir
Publicado 2020

Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study

por Peled, Nir, Kian, Waleed, Inbar, Edna, Goldstein, Iris M, Zemel, Melanie, Rotem, Ofer, Rozenblum, Anna B, Nechushtan, Hovav, Dudnik, Elizabeth, Levin, Daniel, Zer, Alona, Keren-Rosenberg, Shoshana, Yust-Katz, Shlomit, Fuchs, Vered, Remilah, Areen A, Shelef, Ilan, Roisman, Laila C
Publicado 2021